<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488941</url>
  </required_header>
  <id_info>
    <org_study_id>Metabolic liver function NAFLD</org_study_id>
    <nct_id>NCT02488941</nct_id>
  </id_info>
  <brief_title>Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic&#xD;
      liver disease in the western world and an important cause of morbidity and mortality&#xD;
      including risk of cardiovascular disease. A ruling dogma is that a fatty liver is&#xD;
      well-functioning. Recent studies imply the contrary but quantitative measurements of&#xD;
      metabolic liver function have not been systematically investigated in NAFLD.&#xD;
&#xD;
      Objectives: To study and quantify specific metabolic liver functions in varying degrees of&#xD;
      NAFLD. Furthermore to map the coagulation system of patients with NAFLD.&#xD;
&#xD;
      Methods: A human clinical study. Metabolic liver functions are studied by a series of&#xD;
      functional tests (Galactose elimination capacity (GEC), Aminopyrine breath test (ABT),&#xD;
      Indocyanine green plasma disappearance rate (ICG-PDR), Functional hepatic nitrogen clearance&#xD;
      (FHNC)). Regional liver function evaluated by 2-[18F]fluoro-2-deoxy-D-galactose (FDGal)&#xD;
      PET/CT is compared to fat infiltration assessed by Magnetic resonance imaging (MRI). Primary&#xD;
      and secondary hemostasis, natural anti-coagulants and fibrinolysis are evaluated.&#xD;
&#xD;
      Perspectives: To challenge the dogma, that hepatic metabolic function is not affected in&#xD;
      NAFLD, improving the understanding of the relationship between the clinical degree of NAFLD,&#xD;
      histology, metabolic functions, and imaging. Furthermore to disclose a proposed procoagulant&#xD;
      imbalance in NAFLD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic Liver Function assessed by GEC</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Liver Function assessed by FHNC</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Liver Function assessed by ABT</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Liver Function assessed by ICG-PDR</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Regional metabolic liver function evaluated by FDGal PET/CT</measure>
    <time_frame>Baseline</time_frame>
    <description>100 megabecquerel FDGal is injected intravenously in the beginning of a 20 min PET recording and 3D images of regional metabolic liver function expressed in terms of hepatic metabolic clearance of FDGal is created.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Regional fat infiltration assessed by MRI</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary hemostasis</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary hemostasis</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural anti-coagulants</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinolysis</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver biopsy Blood : serum and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with varying degrees of NAFLD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Hepatic steatosis found on ultrasound&#xD;
&#xD;
          -  Clinical indication for liver biopsy (typically persistently elevated alanine&#xD;
             transaminase (ALT) levels)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other liver pathology&#xD;
&#xD;
          -  Alcohol consumption &gt; 20g/day&#xD;
&#xD;
          -  Chronic inflammatory disease, current infection or cancer&#xD;
&#xD;
          -  Diabetes mellitus type I, II or HbA1c ≥ 48 mmol/mol (6.5 %)&#xD;
&#xD;
          -  Prednisolone treatment within last 8 weeks&#xD;
&#xD;
          -  Pregnancy within last 12 months&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Vilstrup, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Hepatology &amp; Gastroenterology, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Lykke Eriksen, MD</last_name>
    <phone>+45 7846 4076</phone>
    <email>ple@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hepatology &amp; Gastroenterology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Vonsild</last_name>
      <phone>+45 7846 3892</phone>
      <email>marianne.vonsild@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Function Tests</keyword>
  <keyword>Blood Coagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

